NCT03510624 (AREBAG) is a Phase 1 clinical trial of Rebaudioside A in Type 2 Diabetes Mellitus, sponsored by Universitaire Ziekenhuizen KU Leuven.

Who is sponsoring NCT03510624?

NCT03510624 is sponsored by Universitaire Ziekenhuizen KU Leuven.

What drugs are being tested in NCT03510624?

Interventions in NCT03510624: Rebaudioside A, Placebo.

What condition does NCT03510624 study?

NCT03510624 studies Type 2 Diabetes Mellitus.

Is NCT03510624 still recruiting?

NCT03510624 is currently completed. Last updated 28 April 2021.

Last reviewed 2021-04-28 · How we verify

NCT03510624: AREBAG

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acute Effect of Rebaudioside A on Glucose Excursion During an Oral Glucose Tolerance Test in Type 2 Diabetes Mellitus

Completed Phase 1 Last updated 28 April 2021

What this trial tests

Phase 1 trial testing Rebaudioside A in Type 2 Diabetes Mellitus in 30 participants. Completed in 1 April 2021.

Timeline

9 November 2018

Primary endpoint
1 April 2021

1 April 2021

Quick facts

Lead sponsor	Universitaire Ziekenhuizen KU Leuven
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	9 November 2018
Primary completion	1 April 2021
Estimated completion	1 April 2021
Sites	1 location across Belgium

Drugs / interventions tested

Rebaudioside A — full drug profile →
Placebo

Conditions studied

Type 2 Diabetes Mellitus — all drugs for Type 2 Diabetes Mellitus →

Sponsor

Universitaire Ziekenhuizen KU Leuven — full company profile →

Who can join

Adults 35 to 75, any sex, with Type 2 Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Investigate the acute effect of the steviol glycoside, rebaudioside A, on the glucose excursion during an oral glucose tolerance test in 30 patients with type 2 diabetes mellitus.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pharmacokinetics of Oral Rebaudioside A in Patients with Type 2 Diabetes Mellitus and Its Effects on Glucose Homeostasis: A Placebo-Controlled Crossover Trial.
Simoens C, Philippaert K, Wuyts C, Goscinny S, et al · · 2022 · cited 6× · PMID 36057030 · DOI 10.1007/s13318-022-00792-7

Verify or expand the search:

Other trials of Rebaudioside A

Trials testing the same drug.

NCT05287906 — A Trial to Assess Steviol Glycosides on Acute Appetite Hormone Release · NA · completed

Other recruiting trials for Type 2 Diabetes Mellitus

Currently open trials in the same condition.

NCT07351058 — A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes · Phase 3 · recruiting
NCT07373938 — Carotid Wall Texture as a Cardiovascular Risk Biomarker in Type 2 Diabetes Mellitus · recruiting
NCT07433062 — A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With · Phase 1 · recruiting
NCT07276776 — An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes · NA · active not recruiting
NCT07232537 — An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic · recruiting

Other Universitaire Ziekenhuizen KU Leuven trials

Trials by the same sponsor.

NCT06831955 — LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer · Phase 2 · recruiting
NCT07356505 — Efficacy and Safety of Micra AV2 Transcatheter Pacing System · NA · recruiting
NCT07286968 — Gastro-Intestinal Digestion and Physiology After Bariatric Surgery · recruiting
NCT06962137 — Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer · Phase 2 · recruiting
NCT07270536 — Accelerated Pacing and Cardiac Filling Pressures During Exercise in Patients With Heart Failure With Preserved Ejection · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03510624 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universitaire Ziekenhuizen KU Leuven
Last refreshed: 28 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03510624.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing